Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Empagliflozin (12.5mg) + Metformin (1000mg)
Therapeutic Category
Antidiabetic, Cardiovascular, Endocrinology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10x10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Emplozin M 12.5/1000 Tablet combines two powerful medications—Empagliflozin and Metformin—to offer effective management of type 2 diabetes mellitus. Empagliflozin, an SGLT2 inhibitor, helps lower blood sugar by preventing glucose reabsorption in the kidneys, leading to its excretion through urine. Metformin, a biguanide, works by improving the body’s sensitivity to insulin, reducing glucose production in the liver, and enhancing insulin utilization in the muscles.
The combination of these two active ingredients provides dual action to control high blood sugar, making it an ideal choice for individuals with type 2 diabetes who require comprehensive glycemic control. This combination therapy not only helps to lower blood sugar levels but also assists in weight management and has potential cardiovascular benefits, reducing the risk of heart-related complications.
May cause gastrointestinal issues (nausea, diarrhea), urinary tract infections, dehydration, and rare cases of lactic acidosis or kidney issues.
Indicated for the treatment of type 2 diabetes mellitus to improve blood sugar control when used in combination with diet and exercise.
Contraindicated in severe kidney disease; follow healthcare provider’s instructions carefully.
Store below 30°C in a cool, dry place, away from moisture and light. Keep out of reach of children.
Composition : Empagliflozin (25mg) Tablet
Composition : Empagliflozin (10mg) Tablet
Composition : Empagliflozin (12.5mg) + Metformin (500mg)
Composition : Empagliflozin (5mg) + Metformin (500mg)
Composition : Empagliflozin (10mg) + Sitagliptin 100mg
Composition : Empagliflozin (25mg) + Sitagliptin (100mg) Tablet
Composition : Empagliflozin 10mg + Sitagliptin 100mg + Metformin 1000mg (extended release)
Composition : Empagliflozin 25mg + Sitagliptin 100mg + Metformin 1000mg (extended release)
Composition : Empagliflozin (10mg) + Linagliptin (5mg)
Composition : Empagliflozin (25mg) + Linagliptin (5mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This anti-diabetic combination is widely used in type 2 diabetes management, making it a strong prescription product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes, blood sugar control, insulin resistance management, cardiovascular risk reduction support, and long-term glycemic control. It is commonly prescribed by diabetologists and physicians for improved diabetes management and patient compliance.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Empagliflozin 12.5mg + Metformin 1000mg Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong chronic prescription demand, growing diabetic patient populations, repeat monthly therapy usage, and high acceptance in diabetology and general medicine segments when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this anti-diabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.